Introduction
End-organ damage associated with cardiovascular disease is the leading cause of morbidity and mortality in the Western world. Moreover, the costs related to the end-organ damage, such as chronic kidney or heart failure, constitute the majority of expenditures in the total health care budget 1 . Therefore, a shift is required from secondary prevention of renal and cardiac end-organ damage to primary prevention targeting the individuals with an increased risk profile at an early stage of the disease. Disclosure of novel markers for increased risk may help to identify specific individuals and assist in tailoring prevention according to their individual risk profile. In addition to traditional cardiovascular risk factors, such as hypertension, dyslipidemia, central obesity, hyperglycemia and smoking, microalbuminuria has recently received a great deal of attention as a new, accessible and sensitive marker of renal and cardiovascular risk [2] [3] [4] . The mechanisms linking microalbuminuria to increased renal and cardiovascular risk are not fully understood, but it has been proposed that microalbuminuria is a reflection of generalized endothelial dysfunction 5 . This review summarizes the current knowledge about the intricate relationship between microalbuminuria and endothelial dysfunction. It focuses on the role of these two parameters as early markers of both renal and cardiovascular disease. Based on the current evidence we suggest that microalbuminuria and endothelial dysfunction represent emerging targets for primary prevention strategies. Since endothelial dysfunction is frequently characterized by decreased bioavailability of nitric oxide (NO), we propose that dietary components improving NO bioavailability, such as cocoa-derived flavanols, may play important role in these preventive strategies.
Microalbuminuria Definition
Albumin is the major constituent of proteins excreted in urine. The widely used dipstick method detects only albumin excretion exceeding 300 mg per 24h, a range currently defined as macroalbuminuria or proteinuria. However, studies in diabetic patients demonstrated that much lower values of albumin excretion are associated with increased risk for the development of diabetic nephropathy 6, 7 Currently, the range between 30 and 300 mg per 24h, or 20-200 µg/min measured overnight is defined as microalbuminuria.
Methods for the measurements of urinary albumin, its definition and classification have been extensively summarized elsewhere 8, 9 Microalbuminuria is not rare in normal healthy population Prevalence of microalbuminuria has been initially studied in individuals with diabetes and later in hypertensive cohorts. Still, a large variability is reported in distinct clinical trials, probably due to heterogeneity of the study population, regarding age, race, severity of hypertension, coexistence of nephropathy, antihypertensive medication and associated lipid abnormalities. Methods of detection and sampling techniques might form an additional source of variation among trials. In general, a prevalence of 20-40% in patients with diabetes mellitus is reported in large studies [10] [11] [12] [13] . In the individuals with essential hypertension the prevalence of microalbuminuria seems somewhat lower 14, 15 . As an example, microalbuminuria was found in 23% of patients with essential hypertension and left ventricular hypertrophy included in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study 16 .
Increased incidence of microalbuminuria is not exclusively limited to the populations with elevated cardiovascular risk. An increasing number of large trials suggest that microalbuminuria is also common in a general, "healthy" population. In one of the largest cohorts studying a general population, the Prevention of Renal and Vascular End stage Disease (PREVEND) study, a prevalence of 7.2% was reported in 40.856 subjects and 6.6% after exclusion of the subjects with diabetes mellitus and hypertension 17 . Several other cross-sectional studies confirm 5-8% prevalence of microalbuminuria in the general population [18] [19] [20] , suggesting that among healthy individuals a considerable variability in urinary albumin excretion already exists without the presence of any clinical condition. This phenomenon renders microalbuminuria a promising candidate as the integrated marker of cardiovascular risk in the general population.
Microalbuminuria predicts renal and cardiovascular outcome in diseased and healthy population Considerable attention for microalbuminuria as a predictive parameter stemmed from the publication of Viberti et al. establishing the predictive value of microalbuminuria for nephropathy in insulin-dependent diabetes mellitus 7 . Since then several studies have confirmed elevated albumin excretion as a marker for the development of diabetic nephropathy and progressive renal failure both in patients with type I 6 and type II diabetes 21 . However, the predictive value of microalbuminuria in diabetics is not only limited to renal events, as microalbuminuria predicts total and especially cardiovascular mortality and morbidity in several studies in non-insulin-dependent diabetic populations 23 even after adjustment for other conventional cardiovascular risk factors. Yudkin et al. were the first to report this association also in non-diabetic subjects 24 . By now, it is well established that microalbuminuria identifies the individuals with adverse prognosis among hypertensive patients. In one of the largest longitudinal studies performed to investigate a predictive role of microalbuminuria, the Danish MONICA study, hypertensive subjects with albuminuria showed almost 4-fold increased risk of ischemic heart disease as compared to normoalbuminuric hypertensive subjects 25 . In the prospective LIFE trial in non-diabetic hypertensive patients with left ventricular hypertrophy, levels of albumin excretion at entry were predictive for composite end-point 26 . Since there was no threshold for the increased risk, correlation between albuminuria and risk exists also at albumin levels below the current definition of microalbuminuria.
Whereas microalbuminuria is clearly related to cardiovascular risk in high risk populations, it is important to mention that its predictive value also extrapolates to the general population. In the previously mentioned prospective Danish MONICA study, microalbuminuric subjects in general population were at increased risk for ischemic heart disease 27 . Furthermore, Hillege et al. demonstrated that microalbuminuria was independently associated with cardiovascular risk factors and morbidity in the general population, based on cross-sectional analysis of the baseline data from the PREVEND study 17 . In a more recent prospective analysis of this study, microalbuminuria
independently predicted cardiovascular and all-cause mortality in the general population (Figure 1 ) 22 . Moreover, the relationship was already apparent at levels of albumin excretion considered to be normal. Within the same cohort, Verhave et al. showed that subjects with microalbuminuria at baseline had a higher chance to develop de novo impairment of renal function in a 4-year follow-up 28 . 
Endothelial dysfunction
The concept of endothelial dysfunction The concept of endothelial dysfunction has emerged from cardiovascular research over the past 25 years, recognizing the principal role of the endothelium in regulation of vascular function in healthy individuals and its impairment in diseased states 29, 30 . Endothelial dysfunction is now considered to play a principal role in the initiation and progression of atherosclerosis. Since endothelial dysfunction is also a common denominator for a wide variety of conditions such as hypertension, diabetes or chronic renal failure, it may provide a link to increased cardiovascular risk in above mentioned conditions. Endothelial dysfunction may be defined as alterations in the normal properties of endothelium that are inappropriate for preservation of organ function 31 . Under physiological circumstances, the endothelium maintains homeostasis at the vascular wall. Normal healthy endothelium reduces vascular tone, regulates vascular permeability, limits platelets adhesion and aggregation, prevents activation of the coagulation cascade and restricts leukocyte adhesion. The specific term endothelial activation denotes the loss of endothelial anti-inflammatory properties characterized by elevated expression of adhesive molecules, such as E-selectin, intracellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1) and chemoattractant molecules e.g. monocyte chemotactic protein-1 (MCP-1), and consequently pronounced interaction with blood leukocytes. Functional properties of endothelium and involved mediators are summarized in Table 1 . One of the most important mediators released by endothelium is nitric oxide (NO) 32 . NO acts a potent vasodilator, inhibits inflammation, growth of vascular smooth muscle and aggregation of platelets. Altered production and/or bioavailability of NO are frequently reported in the conditions associated with endothelial dysfunction. However, the mechanisms responsible for the development of endothelial dysfunction are not yet completely understood. Probably the convergence of traditional and non-traditional risk factors, genetic predisposition and local, yet unknown mechanisms all contribute to endothelial perturbations 32 . Summary of the mechanisms playing a role in endothelial cell dysfunction is given in Table 2 . Several methods are available for investigation of endothelial function in humans, which however assess only certain aspects of endothelial function. Measurements of endothelium-dependent vasodilation assess determines abilities of endothelium in coronary, forearm resistance or brachial arteries. Transcapillary escape rate of intravenously injected radioactive albumin is employed as a surrogate for endothelial microvascular permeability. Finally, plasma levels of endothelium-derived regulatory mediators, such as Von Willebrand factor (vWF), soluble thrombomodulin, tissue-type plasminogen-activator (tPA), plasminogen activator inhibitor-1 (PAI-1), soluble adhesive (selectins, ICAM-1, VCAM-1) and chemoattractant molecules (MCP-1) could be used to estimate systemic endothelial activation. The current evidence for the association of microalbuminuria with several aspects of endothelial dysfunction in humans is summarized below. Furthermore, one study demonstrated that microalbuminuria was related to systemic vascular leakage even in healthy subjects 35 . Although microalbuminuria seems to be consistently associated with increased systemic leakage of albumin, some studies found increased albumin escape rate also in the hypertensive subjects with normoalbuminuria 36,37 ,
suggesting that increased permeability of systemic microvessels is not always reflected in glomerular protein leakage. Although it is difficult to draw final conclusion from these findings, it might be suggested that in these states development of systemic vascular protein leakage actually precedes the appearance of microalbuminuria. Intriguing is the fact that these findings could be extended from high risk populations to cohorts with clinically healthy subjects. Clausen et al. found that brachial artery flowdependent dilation was significantly impaired in healthy individuals with microalbuminuria as compared to those with normoalbuminuria 45 . However, it should be noted that some studies failed to find direct relationship between endothelial dysfunction and urinary albumin excretion in essential hypertensives 46 and healthy subjects 47 . In fact, blunted systemic endothelium-mediated dilatory response is often found also in normoalbuminuric diabetic subjects [48] [49] [50] , strongly suggesting that impaired endothelial function precedes the development of microalbuminuria.
Impaired systemic endothelium-dependent vasodilation

Elevated plasma levels of pro-thrombotic and pro-inflammatory endothelial markers
Increased plasma levels of inflammatory and pro-thrombotic markers have also been reported from the various cohorts of patients with microalbuminuria suggesting that elevated urinary excretion of albumin is associated with generalized endothelial activation and a low-grade inflammatory state. Higher circulating levels of von Willebrand factor (vWF) were found in patients with hypertension and microalbuminuria as compared to those without microalbuminuria 51 . In addition to vWF, other markers of a procoagulant state, such as plasminogen activator inhibitor-1 (PAI-1) and coagulation factor VII are elevated in both insulin-dependent 52 63 . Furthermore, baseline levels of vWF were strongly related to the de novo development of microalbuminuria in the follow-up of non-insulin-dependent diabetic cohort 64 . Comparable data have also been found in a low-risk population. In a 4-year prospective study performed in healthy subjects, baseline elevated levels of vWF and tissue plasminogen activator (t-PA) predicted the development of increased urinary albumin excretion 65 . Simultaneously to impaired endothelium-dependent dilation, increased levels of soluble adhesive molecules are already present in normoalbuminuric diabetic subjects, a finding consistent with the hypothesis on the endothelial dysfunction appearing prior to microalbuminuria 66 .
In conclusion, microalbuminuria is associated with increased in systemic albumin permeability, impaired endothelium-vasodilation of systemic vasculature and elevated levels of pro-inflammatory and pro-thrombotic endothelium-derived mediators. This is not only true in diabetic and hypertensive patients, but also in healthy subjects. Prevailing evidence suggests that in some of these states endothelial dysfunction actually precedes the development of microalbuminuria.
Prognostic value of endothelial function for cardiovascular risk
Present data consistently confirm that increased urinary excretion of albumin might be a useful integrated early marker of renal and cardiovascular risk. On the other hand, prognostic value of endothelial function is still a matter of debate. Since recognition of principal role of endothelial dysfunction in the development of atherosclerosis, several studies have been designed to investigate prognostic value of endothelial dysfunction for cardiovascular outcome. However, reports from microalbuminuric cohorts are scarce. Most of the studies investigated endothelial dilatory reactivity as a marker of endothelial dysfunction. Coronary or peripheral endothelium-mediated response in patients with mild, moderate or established coronary artery disease predicted the adverse event rates in several studies [67] [68] [69] [70] . Prognostic value of peripheral endothelial vasodilation has been also shown in patients with end-stage renal disease 71 and chronic heart failure 72 . The predictive value of endothelial function in patients with normal coronary angiograms 73 , cohort of essential hypertensives 74 and hypertensive postmenopausal women 75 might suggest that this measurement could identify patients at risk at very early stage of the cardiovascular disease. Alternatively, the prognostic value of endothelium-derived regulatory markers in plasma has been reported from several studies. Once more, the majority of studies was performed in patients with known coronary disease. In these cases, vWF, t-PA 76 , PAI-1 77 , soluble ICAM-1 78 and endothelin 79 were predictors of cardiovascular events. In one of the few studies with a low risk population, Ridker et al. found elevated plasma levels of soluble ICAM-1 to predict the risk for future myocardial infarction in healthy men 80 . Studies investigating the predictive value of endothelial dysfunction in patients with microalbuminuria are sporadic and the relation between these two parameters in predicting the cardiovascular outcome is not straightforward. Jager et al. have found plasma levels of VCAM-1 being predictive for cardiovascular outcome in type II diabetics independently from microalbuminuria 81 , suggesting that increased plasma levels of VCAM-1 might reflect a different aspect of endothelial dysfunction than microalbuminuria. The same group showed that cardiovascular risk predicted by microalbuminuria is modified by presence of elevated levels of vWF and retinopathy in type II diabetics, favouring the conclusion, that "benign" microalbuminuria (without concomitant presence of endothelial dysfunction) has more favourable prognosis than "malign" microalbuminuria (with endothelial dysfunction) 82, 83 .
In conclusion, predictive value of the endothelial dysfunction for cardiovascular outcome has been shown mostly in high risk patients. Although some data suggest that this relationship exists in low risk, healthy or microalbuminuric populations, further studies will be needed to establish it conclusively.
Microalbuminuria and endothelial dysfunction as therapeutic target
Presence of microalbuminuria is consistently associated with worse cardiovascular outcome in several diseased conditions and in the general population. Therefore, it is of importance to explore, whether limiting of microalbuminuria provides benefit for decreased cardiovascular risk. Given the early occurrence of endothelial dysfunction in microalbuminuric patients, modulation of endothelial function might provide an additional strategy to limit adverse cardiovascular events. Furthermore, the both parameters emerge as therapeutic targets for primary prevention in the general population.
Lowering of albumin excretion is associated with reduction of cardiovascular risk
Several therapeutic approaches reverse the excessive urinary excretion of proteins. Strict glucose control may prevent the development of microalbuminuria in diabetics 84 .
Furthermore, several studies showed that angiotensin-converting enzyme inhibitors (ACEi) [85] [86] [87] , angiotensin II AT1 receptor blockers (ARB) 88, 89 , lipid-lowering drugs, such as statins 90, 91 or fibrates 92 and recently also oral glycosaminoglycane sulodexide 93, 94 all reduce or even regress microalbuminuria in patients with type I or type II diabetes. Tight blood pressure control is required to halt the progression of microalbuminuria in hypertensive patients, however drugs interfering with renin-angiotensin-aldosterone system (RAAS) might provide more benefit than diuretic, beta-blocking agents or calcium channel blockers in lowering albuminuria 95 . Importantly, available evidence suggests, that specific lowering of microalbuminuria translates in the reduction of renal and cardiovascular adverse events in several populations. Parving et al. showed that lowering of albuminuria with ARB irbesartan is dosedependently associated with reduced progression to diabetic nephropathy in hypertensive type II diabetics independent of blood pressure control 88 . Comparably, several other studies demonstrated efficacy of ACEi in preventing diabetic nephropathy in diabetic microalbuminuric patients 85, 96 . In the LIFE study among hypertensive patients with left ventricular hypertrophy, a reduction in albumin excretion was inversely related to the risk of cardiovascular mortality and morbidity 97 . It seems that drugs interfering with the RAAS are superior to other antihypertensives, also in reducing cardiovascular events in microalbuminuric subjects. This is however largely based on the data from hypertensive diabetic populations, which are known to have high incidence of microalbuminuria [98] [99] [100] . Recent compelling evidence for microalbuminuria as a justified target for primary prevention comes from the PREVEND-IT study 101 . Healthy individuals with microalbuminuria, but without hypertension or hypercholesterolemia, were treated either with placebo or the ACEi fosinopril. At 4-year's follow-up, the microalbuminuria was effectively reduced by ACEi treatment, which was associated with a 44% reduction in cardiovascular events.
In conclusion, lowering of urinary albumin excretion, preferably by RAAS inhibitory agents substantially reduces the number of cardiovascular events in both high risk and healthy population.
Table 3. Intervention strategies leading to reversal of endothelial dysfunction in humans
General interventions
Physical activity 
Modulation of endothelial dysfunction in microalbuminuric patients
A wide spectrum of treatments (Table 3 ) has been shown to improve endothelial dysfunction in several conditions. However, the hypothesis, that reversal of endothelial dysfunction is associated with risk reduction has not been directly tested. Nevertheless, some of endothelium-protective therapeutic strategies, such as ACEi 102 , ARB 103 , and statins 104 have been consistently shown to reduce cardiovascular events in multiple populations. It is however unclear to what extent the improvement in endothelial function governs cardiovascular risk reduction. A limited number of studies is available on reversing endothelial dysfunction in patients with microalbuminuria. Strikingly, all therapeutic approaches associated with lowering microalbuminuria are also known to improve endothelial function. Therefore it is tempting to speculate that improvement of endothelial function plays role in the beneficial effects of these drugs on albumin urinary excretion and probably in cardiovascular risk reduction. However, the current data from diabetic patients do not allow such conclusion on this issue. Several trials investigated the effect of ACEi and ARB treatment on the peripheral endothelial function in diabetic microalbuminuric patients. While in type I diabetics Arcaro et al. 105 found ACEi to improve endothelium-dependent vasodilation of femoral artery without affecting microalbuminuria, Schalkwijk et al. reported unchanged peripheral endothelium-dependent dilation after short-term therapy with ACEi quinapril 106 . However, in the latter study ACEi reduced plasma levels of soluble E-selectin, suggesting that some aspects of endothelial dysfunction were selectively improved. Similarly, reversal of elevated VCAM-1 levels paralleled the decrease of microalbuminuria by fosinopril in hypertensive type II diabetics 107 . In contrast, a low dose of ARB losartan, which did not affect blood pressure, did not have any impact on peripheral endothelial dilation, while it reduced microalbuminuria 108 . Overall, studies with RAAS interfering agents suggest that these drugs may improve several aspects of endothelial function in microalbuminuric diabetic subjects, but it is not clear whether these effects play role in their anti-albuminuric action. Factors such as duration of treatment, population and agent characteristics might underlie these discrepancies. In addition to ACEi and ARB, one study investigated the effect of atorvastatin on brachial artery flow-mediated dilation in microalbuminuric type I diabetics. Six weeks treatment improved vasodilation, but had no effect on albumin excretion, probably due to the short duration of the treatment 109 . Therefore also statins may prove beneficial in reversing endothelial dysfunction in microalbuminuric diabetic patients.
In conclusion, the available data provide evidence that lowering microalbuminuria especially by RAAS modulating agents in diabetics, hypertensives and even in healthy subjects might provide benefits in terms of reduced cardiovascular events. Majority of the agents efficiently lowering microalbuminuria might also reverse endothelial dysfunction. However a role of the endothelial modulation in risk reduction remains unclear. Nevertheless, experimental evidence suggesting that endothelial dysfunction precedes microalbuminuria and that variability in endothelial dysfunction among healthy individuals determines the end-organ damage renders endothelial dysfunction the important modifiable factor for primary prevention.
Future potential of dietary flavonoids in primary prevention of microalbuminuria
Data from the PREVEND-IT study clearly show that reduction of microalbuminuria among healthy subjects might prevent future cardiovascular events. Although modulation of microalbuminuria and endothelial dysfunction might be the most efficiently achieved by ACEi or ARB, additional strategies might prove useful in primary prevention. Furthermore, as reported from PREVEND-IT cohort, in otherwise-healthy microalbuminuric population only 63% of subjects were compliant to ACEi treatment. Therefore, for primary prevention, dietary supplements might provide more acceptable and inexpensive alternative to pharmaceutical compounds. Recently, attention has been drawn to several nutritional factors in prevention of cardiovascular disease. Majority of the research concentrated on n-3 fatty acids, antioxidant vitamins, L-arginine, folic acid and plant-derived polyphenols. The latter can be present in relatively high concentrations in certain plant-based foods and beverages, such as red wine, tea, grapefruit juice or cocoa-based products 110 . This makes them potentially interesting candidates for primary prevention. Several studies performed both in high and low risk populations suggest beneficial effect of these supplements on cardiovascular outcome 111, 112 . These benefits seem to be mediated by improved endothelial function. Indeed, plant polyphenols, especially flavonoids have been shown to improve endothelial function in experimental and human studies 113, 114 . Even more important for primary prevention is the fact that endothelium-protective characteristics of flavonoids, such as increase in nitric oxide bioavailability due to antioxidant properties or stimulating effects on endothelial nitric oxide synthase, have been found in healthy individuals. This suggests the potential of flavonoids to modify healthy endothelial function and thereby modulate individual sensitivity to cardiovascular injury. Although the flavonoids content is variable among the various dietary products and is also dependent on food processing practices, it appears that raw cocoa might contain the concentrations of specific flavonoids substantially exceeding most other known sources 115 .
Beneficial vascular effects of cocoa-based products, probably attributed to subclass of flavonoids known as flavanols, has been recently extensively reported 116, 117 . Impressive studies in healthy humans have shown that ingestion of flavanol-rich cocoa is associated with increased NO-dependent vasodilation 118 , reduced wave reflections 119 , decrease in blood pressure and even an increase in insulin sensitivity 120 . Beneficial effects on endothelial function and insulin sensitivity were also confirmed in smokers 121 and hypertensives 122 . Although the effects of cocoa flavanols on renal vasculature and albumin excretion await further investigation, dietary strategies utilizing flavanol-rich cocoa hold a promise as a primary preventive approach in subjects with microalbuminuria.
Conclusion
In conclusion, microalbuminuria is an early and sensitive marker of renal and cardiovascular risk in both high and low risk patients. Most likely, it reflects a state of generalized endothelial dysfunction. Modulation of microalbuminuria and endothelial function might provide beneficial effects on future cardiovascular outcome even in the general or healthy population. Therefore, targeting microalbuminuria and endothelial dysfunction by several agents, such as ACE inhibitors or angiotensin receptor blockers might provide an effective strategy for primary prevention of renal and cardiovascular disease. Inexpensive and well tolerated dietary strategies utilizing plant-based products such as flavanol-rich cocoa might prove useful for primary prevention of end-organ damage in the general population. 
